N/A
N=186
Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With PCV10
Pneumococcal Infections
Bottom Line
View on ClinicalTrials.gov: NCT04912297 ↗Enrolled (actual)
186
Serious AEs
0.0%
Results posted
Aug 2021
Primary outcome: Primary: Persistence of Humoral Immunity Following PCV10 Vaccination — 0.32; 0.35 micrograms per ml
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- 10-valent pneumococcal conjugate vaccine, PCV10 (Biological)
- Age
- Pediatric · 0+ yrs
- Sex
- All
- Sponsor
- Finnish Institute for Health and Welfare
- Primary completion
- May 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Persistence of Humoral Immunity Following PCV10 Vaccination |
0.32; 0.35 | — |
Summary
The aim of the study are to assess the persistence of immunity against vaccine serotypes (VSTs) and vaccine-related serotypes in PCV10 vaccinated children in Finland.
Eligibility Criteria
Inclusion Criteria
- Completed PCV10 vaccination with 3 or 4 doses (2+1 or 3+1 schedule) before blood sampling at age of 13 months
- Age at sample collection 13 months, 2 years or 3 years
- PCV10 vaccination received 2-6 weeks before sample collection at the age of 1 year
- Informed consent obtained covering the planned analyses
Exclusion Criteria
- PCV13 or PPV23 dose received
- Informed consent withdrawn
Data sourced from ClinicalTrials.gov (NCT04912297). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.